spacer
home > epc > spring 2009 > centralising ecgs
PUBLICATIONS
European Pharmaceutical Contractor

Centralising ECGs

Cardiac safety has become the number one reason for drug withdrawals and labelling changes during the past several years. This has resulted in greater regulatory scrutiny for all new compounds and greater concern among pharmaceutical companies in regard to the potential effect of their compounds on cardiac safety. One of the outcomes of this focus was the ICH E14 document, which provided guidance on the conduct of a dedicated ECG study which many term the ‘thorough QT (TQT) trial’ (1). These trials are generally conducted after proof of concept has been completed and employ digital and centralised ECGs as described in E14. However, although  almost all TQT trials are centralised, only approximately 20 to 25 per cent of all other clinical research (Phases I-IV) trials use centralised ECG analyses.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Jeffrey S Litwin is a board certified Internist and Cardiologist. He left his cardiology practice in 1988 to serve as Director, Medical Affairs at Wyeth-Ayerst Laboratories. Jeffrey has been providing consultative support to the pharmaceutical industry for the design and conduct of cardiac safety trials and to the device industry for the design of ECG and Holter technologies for over 15 years. He is currently an Executive Vice President and the Chief Medical Officer for eResearchTechnology ERT), which he joined in July, 2000.

spacer
Jeffrey S Litwin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement